“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”
A study to see how genes affect response to the hormone therapy letrozole in women with advanced breast cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This study was looking at blood and tissue samples and linking them to side effects and treatment outcome in women taking the hormone therapy letrozole (Femara) for advanced breast cancer.
People respond to medication in different ways. For example, the same cancer treatment may cause side effects in one person, such as sickness, but not in another. Or someone having a particular drug may have a better outcome than someone else taking the same drug for the same type of cancer. We know from research that the inherited instructions in our cells (our
Researchers had already developed tests to help doctors tell in advance how people will respond to cancer treatment. In this study, researchers wanted to test how useful these methods were in predicting side effects and treatment outcome in different people. They studied blood and tissue samples of women taking the hormone therapy letrozole for advanced breast cancer. They also found out more about the side effects and treatment results they had. The main aims of this study were to
- Identify genes which may help predict which treatment works best for different people, and who will get side effects
- Find out the costs involved in introducing tests to predict treatment outcome in different people
Summary of results
This trial was never finished so there are no results available. The researchers were unable to recruit enough patients.
How to join a clinical trial
Dr William Newman
Breast Cancer Campaign
NIHR Clinical Research Network: Cancer
University of Manchester